Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BCELLSMICETOMEN

Financiado

Cerrado

Translational study on the antigen presenting properties of human vs mouse B cel...

Translational study on the antigen presenting properties of human vs mouse B cell subpopulations Our recent results on antitumor effects of carbohydrate mimotope peptides (CMP) suggest a possible role of carbohydrate reactive B cell subpopulations as cellular adjuvants. As an abundant alternative of dendritic cells, CD40-acti... ver más

14/04/2013

IMicB

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

THE STEPHAN ANGELOFF INSTITUTE OF MICROBIOLOG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-04-14 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IMicB

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

KineTic New Reagents for Quantifying the Routing and Kinetics of T c... 2M€ Cerrado

Crosstag Unravelling cross presentation pathways using a chemical bio... 2M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

PID2020-118529RB-I00 EXPLOTANDO LOS DETERMINANTES MOLECULARES DE LA RESPUESTA T A... 218K€ Cerrado

PHAGODC Integrative phagosomal biology antigen presentation and dev... 2M€ Cerrado

PID2020-116393RB-I00 NUEVA GENERACION DE INMUNOTERAPIAS CONTRA CANCER BASADAS EN... 257K€ Cerrado

Líder del proyecto

THE STEPHAN ANGELOFF INSTITUTE OF MICROBIOLOG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 75K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Our recent results on antitumor effects of carbohydrate mimotope peptides (CMP) suggest a possible role of carbohydrate reactive B cell subpopulations as cellular adjuvants. As an abundant alternative of dendritic cells, CD40-activated B cells can efficiently present specific antigens being expandable for several weeks. Some B cells can be sufficiently detrimental to warrant anti-B cell therapy in cancer. Other (mouse) B cell subsets (e.g. B1 and marginal zone (MZ) B cells) seem as effective as mature DC, including skewing the T cell to the desirable Th1 responses. Thus, B subpopulations deserve scrutiny as the optimal antigen presenting cells. We hypothesize that CMP target carbohydrate reactive B cells, which present the collinear T cell epitopes to auxiliary T cells, create an environment conducive to epitope spreading to glycoprotein tumor antigens. The major mature B cell subpopualtions in the mouse are B2 follicular cells, MZ B cells, as well as B1a and B1b peritoneal B cells. The translation of a B cell strategy to the clinic is hindered by lack of straightforward functional homologies between mouse and human B cell subsets. Therefore, we propose to study the potential of ex vivo expanded human B cell subpopulations to present CMP and induce an appropriate cytokine environment for the development of anti-tumor CTL responses in comparison to the mouse system. To this end we propose to compare the phenotype and antigen presenting properties of mouse and human CMP specific B cells. These studies will allow for the design of therapeutic approaches based on ex vivo expansion of phenotypically similar B cells and using them for active immunotherapy of cancer after loading with appropriate antigens. The relevance of the CMP specific system to a bulk population of the same phenotype stems from the capacity of B cells to present antigens targeted nonspecifically for instance to CD19.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores